Home Food & Medicine Homology Article
PDF (2.8 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Review Article | Open Access | Online First

Resveratrol in degenerative musculoskeletal diseases: a homology of medicine and food perspective

Xuan Zhang1,2,3,4, Hong-Fa Zhou1,2,3,4, Jing-Yuan Chen1,2,3,4, Jin-Hao Deng1,2,3,4, Zi-Meng Zhou1,2,3,4, Hao-Xian Tang4, Jing-Tao Huang4,5, Yi-En Zheng6, Hui Zeng7(), Kai Ren8(), Fei Yu8()
Department of Bone & Joint Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China
National & Local Joint Engineering Research Center of Orthopaedic Biomaterials, Shenzhen 518036, China
Shenzhen Key Laboratory of Orthopaedic Diseases and Biomaterials Research, Shenzhen 518036, China
Shantou University Medical College, Shantou 515041, China
Department of Sports Medicine and Rehabilitation, Peking University Shenzhen Hospital, Shenzhen 518036, China
Institute for Macromolecular Chemistry, University of Freiburg, Freiburg 79104, Germany
Department of Orthopedics, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China
Department of Spine Surgery, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China
Show Author Information

Highlights

(1) Resveratrol’s Therapeutic Potential: Resveratrol helps treat degenerative musculoskeletal diseases (DMDs) by reducing inflammation, oxidative stress, and cell degradation.

(2) Medicine-Food Homology: Resveratrol serves as both a medicine and dietary supplement, supporting long-term DMD management through regular consumption of foods rich in this compound.

(3) Diet-Pharmacology Integration: Combining resveratrol-rich diets with conventional treatments provides a holistic, sustainable approach to DMDs prevention and care.

Graphical Abstract

View original image Download original image
The sources, structure, dual use in medicine and food of resveratrol, and its therapeutic effects along with potential mechanisms on osteoarthritis, osteoporosis, and sarcopenia.

Abstract

This review examines the therapeutic potential of resveratrol (RES) in managing degenerative musculoskeletal diseases (DMDs), including osteoarthritis (OA), osteoporosis, and sarcopenia. With the rising incidence of these diseases in aging populations, effective interventions are increasingly urgent. RES, a polyphenolic compound found in foods such as grapes and peanuts, has shown promise due to its antioxidant and anti-inflammatory properties. Acting within the framework of medicine and food homology, RES holds dual roles as both a dietary supplement and therapeutic agent. RES exerts its effects by modulating various signaling pathways, which collectively reduce inflammation, oxidative stress, and cellular apoptosis, thereby slowing the progression of DMDs. Clinical trials suggest that RES improves bone mineral density, alleviates OA symptoms, and helps preserve muscle mass. However, challenges like limited bioavailability and targeted delivery remain. Future research should focus on optimizing RES’s bioavailability and exploring its synergistic effects with other natural compounds to enhance its therapeutic impact. Overall, RES exemplifies a holistic approach to DMDs management by integrating dietary and pharmacological benefits, offering a sustainable strategy for disease management and prevention.

Keywords

resveratrolosteoarthritisosteoporosissarcopeniamedicine and food homology

References

[1]

Yin, P., Jiang, Y., Fang, X., et al. Cell-Based therapies for degenerative musculoskeletal diseases. Advanced Science, 2023, 10: e2207050. https://doi.org/10.1002/advs.202207050

Crossref Google Scholar
[2]

Wen, Z. Q., Lin, J, Xie, W. Q., et al. Insights into the underlying pathogenesis and therapeutic potential of endoplasmic reticulum stress in degenerative musculoskeletal diseases. Military Medical Research, 2023, 10: 54. https://doi.org/10.1186/s40779-023-00485-5

Crossref Google Scholar
[3]

GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet Rheumatology, 2023, 5: e508–522. https://doi.org/10.1016/S2665-9913(23)00163-7

Crossref Google Scholar
[4]

Ensrud, K. E., Crandall, C. J. Osteoporosis. Annals of Internal Medicine, 2017, 167: ITC17–32. https://doi.org/10.7326/AITC201708010

Crossref Google Scholar
[5]

Yuan, S., Larsson, S. C. Epidemiology of sarcopenia: prevalence, risk factors, and consequences. Metabolism: Clinical and Experimental, 2023, 144: 155533. https://doi.org/10.1016/j.metabol.2023.155533

Crossref Google Scholar
[6]
Guo, J., Huang, X., Dou, L., et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy, 2022 , 7: 391. https://doi.org/10.1038/s41392-022-01251-0
Crossref
[7]

Partridge, L., Deelen, J., Slagboom, P. E. Facing up to the global challenges of ageing. Nature, 2018, 561: 45–56. https://doi.org/10.1038/s41586-018-0457-8

Crossref Google Scholar
[8]

Taruc-Uy, R. L., Lynch, S. A. Diagnosis and treatment of osteoarthritis. Primary Care, 2013, 40: 821–836. https://doi.org/10.1016/j.pop.2013.08.003

Crossref Google Scholar
[9]

Skou, S. T., Roos, E. M. Physical therapy for patients with knee and hip osteoarthritis: supervised, active treatment is current best practice. Clinical and Experimental Rheumatology, 2019, 37: 112–117.

Google Scholar
[10]
Ali, M., Kim, Y. S. A comprehensive review and advanced biomolecule-based therapies for osteoporosis. Journal of Advanced Research, 2024 . https://doi.org/10.1016/j.jare.2024.05.024
Crossref
[11]
Najm, A., Niculescu, A. G., Grumezescu, A. M., et al. Emerging therapeutic strategies in Sarcopenia: an updated review on pathogenesis and treatment advances. International Journal of Molecular Sciences, 2024 , 25: 4300. https://doi.org/10.3390/ijms25084300
Crossref
[12]
Nonomura, S., Kanagawa, H., Makimoto, A. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan, 1963 , 83: 988-990.
Crossref
[13]
Zhang, L. X., Li, C. X., Kakar, M. U., et al. Resveratrol (RV): a pharmacological review and call for further research. Biomedicine & Pharmacotherapy, 2021 , 143: 112164. https://doi.org/10.1016/j.biopha.2021.112164
Crossref
[14]
Huang, X. T., Li, X., Xie, M. L., et al. Resveratrol: review on its discovery, anti-leukemia effects and pharmacokinetics. Chemico-biological Interactions, 2019 , 306: 29–38. https://doi.org/10.1016/j.cbi.2019.04.001
Crossref
[15]
Nadile, M., Retsidou, M. I., Gioti, K., et al. Resveratrol against cervical cancer: evidence from in vitro and in vivo studies. Nutrients, 2022 , 14: 5273. https://doi.org/10.3390/nu14245273
Crossref
[16]

Tian, B., Liu, J. Resveratrol: a review of plant sources, synthesis, stability, modification and food application. Journal of the Science of Food and Agriculture, 2020, 100: 1392–1404. https://doi.org/10.1002/jsfa.10152

Crossref Google Scholar
[17]
Meng, X., Zhou, J., Zhao, C. N., et al. Health benefits and molecular mechanisms of resveratrol: a narrative review. Foods, 2020 , 9: 340. https://doi.org/10.3390/foods9030340
Crossref
[18]

Breuss, J. M., Atanasov, A. G., Uhrin, P. Resveratrol and its effects on the vascular system. International Journal of Molecular Sciences, 2019, 20: 1523. https://doi.org/10.3390/ijms20071523

Crossref Google Scholar
[19]
Zhou, D. D., Luo, M., Huang, S. Y., et al. Effects and mechanisms of resveratrol on aging and age-related diseases. Oxidative Medicine and Cellular Longevity, 2021 , 2021: 9932218. https://doi.org/10.1155/2021/9932218
Crossref
[20]
Hou, C. Y., Tain, Y. L., Yu, H. R., et al. The effects of resveratrol in the treatment of metabolic syndrome. International Journal of Molecular Sciences, 2019 , 20: 535. https://doi.org/10.3390/ijms20030535
Crossref
[21]
Wu, S. X., Xiong, R. G., Huang, S. Y., et al. Effects and mechanisms of resveratrol for prevention and management of cancers: an updated review. Critical Reviews in Food Science and Nutrition, 2023 , 63: 12422–12440. https://doi.org/10.1080/10408398.2022.2101428
Crossref
[22]
Islam, F., Nafady, M. H., Islam, M. R., et al. Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer’s disease from bench to bedside. Molecular Neurobiology, 2022 , 59: 4384–4404. https://doi.org/10.1007/s12035-022-02859-7
Crossref
[23]
Deng, Z., Li, Y., Liu, H., et al. The role of sirtuin 1 and its activator, resveratrol in osteoarthritis. Bioscience Reports, 2019 , 39: BSR20190189. https://doi.org/10.1042/BSR20190189
Crossref
[24]
Ebrahim, H. A., Alzamil, N. M., Al-Ani, B., et al. Suppression of knee joint osteoarthritis induced secondary to type 2 diabetes mellitus in rats by resveratrol: role of glycated haemoglobin and hyperlipidaemia and biomarkers of inflammation and oxidative stress. Archives of Physiology and Biochemistry, 2022 , 128: 1375–1382. https://doi.org/10.1080/13813455.2020.1771378
Crossref
[25]

Shakibaei, M., Buhrmann, C., Mobasheri, A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. The Journal of Biological Chemistry, 2011, 286: 11492–11505. https://doi.org/10.1074/jbc.M110.198713

Crossref Google Scholar
[26]
Huang, Y., Zhu, X., Chen, K., et al. Resveratrol prevents sarcopenic obesity by reversing mitochondrial dysfunction and oxidative stress via the PKA/LKB1/AMPK pathway. Aging (Albany NY ), 2019 , 11: 2217–2240. https://doi.org/10.18632/aging.101910
Crossref
[27]
Valsamidou, E., Amerikanou, C., Tzavara, C., et al. A standardized nutraceutical supplement contributes to pain relief, improves quality of life and regulates inflammation in knee osteoarthritis patients; a randomized clinical trial. Heliyon, 2023 , 9: e20143. https://doi.org/10.1016/j.heliyon.2023.e20143
Crossref
[28]

Thaung Zaw, J. J., Howe, P. R. C., Wong, R. H. X. Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial. Menopause, 2020, 28: 40–49. https://doi.org/10.1097/GME.0000000000001643

Crossref Google Scholar
[29]
Nguyen, C., Boutron, I., Baron, G., et al. Evolution of pain at 3 months by oral resveratrol in knee osteoarthritis (ARTHROL): protocol for a multicentre randomised double-blind placebo-controlled trial. BMJ Open, 2017 , 7: e017652. https://doi.org/10.1136/bmjopen-2017-017652
Crossref
[30]
Wong, R. H., Thaung Zaw, J. J., Xian, C. J., et al. Regular Supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomized, placebo-controlled trial. Journal of Bone and Mineral Research, 2020 , 35: 2121–2131. https://doi.org/10.1002/jbmr.4115
Crossref
[31]
Alway, S. E., McCrory, J. L., Kearcher, K., et al. Resveratrol enhances exercise-induced cellular and functional adaptations of skeletal muscle in older men and women. The Journals of Gerontology, 2017 , 72: 1595–1606. https://doi.org/10.1093/gerona/glx089
Crossref
[32]
Petrella, C., Di Certo, M. G., Gabanella, F., et al. Mediterranean diet, brain and muscle: olive polyphenols and resveratrol protection in neurodegenerative and neuromuscular disorders. Current Medicinal Chemistry, 2021 , 28: 7595–7613. https://doi.org/10.2174/0929867328666210504113445
Crossref
[33]
Sofi, F., Cesari, F., Abbate, R., et al. Adherence to Mediterranean diet and health status: meta-analysis. BMJ, 2008 , 337: a1344. https://doi.org/10.1136/bmj.a1344
Crossref
[34]
Farinetti, A., Zurlo, V., Manenti, A., et al. Mediterranean diet and colorectal cancer: a systematic review. Nutrition, 2017 , 43–44: 83–88. https://doi.org/10.1016/j.nut.2017.06.008
Crossref
[35]
Dyer, J., Davison, G., Marcora, S. M., et al. Effect of a Mediterranean type diet on inflammatory and cartilage degradation biomarkers in patients with osteoarthritis. The Journal of Nutrition, Health & Aging, 2017 , 21: 562–566. https://doi.org/10.1007/s12603-016-0806-y
Crossref
[36]
Mazza, E., Ferro, Y., Pujia, R., et al. Mediterranean diet in healthy aging. The Journal of Nutrition, Health & Aging, 2021 , 25: 1076–1083. https://doi.org/10.1007/s12603-021-1675-6
Crossref
[37]
Chen, L., Huang, D., Jiang, L., et al. A review of botany, phytochemistry, pharmacology, and applications of the herb with the homology of medicine and food: Ligustrum lucidum W.T. Aiton. Frontiers in Pharmacology, 2024 , 15: 1330732. https://doi.org/10.3389/fphar.2024.1330732
Crossref
[38]
Gong, X., Ji, M., Xu, J., et al. Hypoglycemic effects of bioactive ingredients from medicine food homology and medicinal health food species used in China. Critical Reviews in Food Science and Nutrition, 2020 , 60: 2303–2326. https://doi.org/10.1080/10408398.2019.1634517
Crossref
[39]
Martel-Pelletier, J., Barr, A. J., Cicuttini, F. M., et al. Osteoarthritis. Nature Reviews Disease Primers, 2016 , 2: 16072. https://doi.org/10.1038/nrdp.2016.72
Crossref
[40]
Glyn-Jones, S., Palmer, A. J., Agricola, R., et al. Osteoarthritis. Lancet, 2015 , 386: 376–387. https://doi.org/10.1016/S0140-6736(14)60802-3
Crossref
[41]
Silverwood, V., Blagojevic-Bucknall, M., Jinks, C., et al. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthritis and Cartilage, 2015 , 23: 507–515. https://doi.org/10.1016/j.joca.2014.11.019
Crossref
[42]
Van Raemdonck, K., Umar, S., Szekanecz, Z., et al. Impact of obesity on autoimmune arthritis and its cardiovascular complications. Autoimmunity Reviews, 2018 , 17: 821–835. https://doi.org/10.1016/j.autrev.2018.02.007
Crossref
[43]

Abramoff, B., Caldera, F. E. Osteoarthritis: pathology, diagnosis, and treatment options. The Medical Clinics of North America, 2020, 104: 293–311. https://doi.org/10.1016/j.mcna.2019.10.007

Crossref Google Scholar
[44]
Xia, B., Chen, D., Zhang, J., et al. Osteoarthritis pathogenesis: a review of molecular mechanisms. Calcified Tissue International, 2014 , 95: 495–505. https://doi.org/10.1007/s00223-014-9917-9
Crossref
[45]
Prieto-Potin, I., Largo, R., Roman-Blas, J. A., et al. Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis. BMC Musculoskeletal Disorders, 2015 , 16: 226. https://doi.org/10.1186/s12891-015-0664-5
Crossref
[46]
Mimpen, J. Y., Hedley, R., Ridley, A., et al. Cellular characterisation of advanced osteoarthritis knee synovium. Arthritis Research & Therapy, 2023 , 25: 154. https://doi.org/10.1186/s13075-023-03110-x
Crossref
[47]
Xie, C., Chen, Q. Adipokines: new therapeutic target for osteoarthritis? Current Rheumatology Reports, 2019 , 21: 71. https://doi.org/10.1007/s11926-019-0868-z
Crossref
[48]
Salman, L. A., Ahmed, G., Dakin, S. G., et al. Osteoarthritis: a narrative review of molecular approaches to disease management. Arthritis Research & Therapy, 2023 , 25: 27. https://doi.org/10.1186/s13075-023-03006-w
Crossref
[49]
Liu, D., Cai, Z. J., Yang, Y. T., et al. Mitochondrial quality control in cartilage damage and osteoarthritis: new insights and potential therapeutic targets. Osteoarthritis and Cartilage, 2022 , 30: 395–405. https://doi.org/10.1016/j.joca.2021.10.009
Crossref
[50]

Loeser, R. F., Collins, J. A., Diekman, B. O. Ageing and the pathogenesis of osteoarthritis. Nature Reviews Rheumatology, 2016, 12: 412–420. https://doi.org/10.1038/nrrheum.2016.65

Crossref Google Scholar
[51]
Bannuru, R. R., Osani, M. C., Vaysbrot, E. E., et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage, 2019 , 27: 1578–1589. https://doi.org/10.1016/j.joca.2019.06.011
Crossref
[52]
Monsegue, A. P., Emans, P., van Loon, L. J. C., et al. Resistance exercise training to improve post-operative rehabilitation in knee arthroplasty patients: a narrative review. European Journal of Sport Science, 2024 , 24: 938–949. https://doi.org/10.1002/ejsc.12114
Crossref
[53]
Cheng, H. Y., Liang, C. W., Lee, Y. H., et al. Effects of the combination of various pharmacological treatments and exercise on knee osteoarthritis: a systematic review and network meta-analysis. EFORT Open Reviews, 2024 , 9: 668–675. https://doi.org/10.1530/EOR-23-0136
Crossref
[54]
Wang, H., Yuan, T., Wang, Y., et al. Osteoclasts and osteoarthritis: novel intervention targets and therapeutic potentials during aging. Aging Cell, 2024 , 23: e14092. https://doi.org/10.1111/acel.14092
Crossref
[55]
Kumar, A., Palit, P., Thomas, S., et al. Osteoarthritis: prognosis and emerging therapeutic approach for disease management. Drug Development Research, 2021 , 82: 49–58. https://doi.org/10.1002/ddr.21741
Crossref
[56]

Madry, H. Surgical therapy in osteoarthritis. Osteoarthritis and Cartilage, 2022, 30: 1019–1034. https://doi.org/10.1016/j.joca.2022.01.012

Crossref Google Scholar
[57]
Mohamed, K. E., Larsen, A. T., Melander, S., et al. The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection-a novel disease-modifying osteoarthritis drug. Arthritis Research & Therapy, 2024 , 26: 129. https://doi.org/10.1186/s13075-024-03361-2
Crossref
[58]
Sogo, Y., Toyoda, E., Nagai, T., et al. Disease-Modifying effects of lenvatinib, a multiple receptor tyrosine kinase inhibitor, on posttraumatic osteoarthritis of the knee. International Journal of Molecular Sciences, 2024 , 25: 6514. https://doi.org/10.3390/ijms25126514
Crossref
[59]
Yang, H., Zhou, Y., Ying, B., et al. Effects of human umbilical cord mesenchymal stem cell-derived exosomes in the rat osteoarthritis models. Stem Cells Translational Medicine, 2024 , 13: 803–811. https://doi.org/10.1093/stcltm/szae031
Crossref
[60]
Tian, X., Qu, Z., Cao, Y., et al. Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 2024 , 15: 1366297. https://doi.org/10.3389/fendo.2024.1366297
Crossref
[61]
Chen, J., Hao, Z., Li, H., et al. Osteoporotic osseointegration: therapeutic hallmarks and engineering strategies. Theranostics, 2024 , 14: 3859–3899. https://doi.org/10.7150/thno.96516
Crossref
[62]
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International, 2022 , 33: 2049–2102. https://doi.org/10.1007/s00198-021-05900-y
Crossref
[63]

Poole, K. E., Compston, J. E. Osteoporosis and its management. BMJ, 2006, 333: 1251–1256. https://doi.org/10.1136/bmj.39050.597350.47

Crossref Google Scholar
[64]

Vilaca, T., Eastell, R., Schini, M. Osteoporosis in men. The Lancet. Diabetes & Endocrinology, 2022, 10: 273–283. https://doi.org/10.1016/S2213-8587(22)00012-2

Crossref Google Scholar
[65]
Shi, C., Wu, T., He, Y., et al. Recent advances in bone-targeted therapy. Pharmacology & Therapeutics, 2020 , 207: 107473. https://doi.org/10.1016/j.pharmthera.2020.107473
Crossref
[66]

Buck, D. W., Dumanian, G. A. Bone biology and physiology: part I. the fundamentals. Plastic and Reconstructive Surgery, 2012, 129: 1314–1320. https://doi.org/10.1097/PRS.0b013e31824eca94

Crossref Google Scholar
[67]
Mellis, D. J., Itzstein, C., Helfrich, M. H., et al. The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. The Journal of Endocrinology, 2011 , 211: 131–143. https://doi.org/10.1530/JOE-11-0212
Crossref
[68]

Jayakumar, P., Di Silvio, L. Osteoblasts in bone tissue engineering. Proceedings of the Institution of Mechanical Engineers, 2010, 224: 1415–1440. https://doi.org/10.1243/09544119JEIM821

Crossref Google Scholar
[69]

Ono, T., Nakashima, T. Recent advances in osteoclast biology. Histochemistry and Cell Biology, 2018, 149: 325–341. https://doi.org/10.1007/s00418-018-1636-2

Crossref Google Scholar
[70]

Adams, J. E. Advances in bone imaging for osteoporosis. Nature Reviews Endocrinology, 2013, 9: 28–42. https://doi.org/10.1038/nrendo.2012.217

Crossref Google Scholar
[71]
Ikebuchi, Y., Aoki, S., Honma, M., et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature, 2018 , 561: 195–200. https://doi.org/10.1038/s41586-018-0482-7
Crossref
[72]

Rachner, T. D., Khosla, S., Hofbauer, L. C. Osteoporosis: now and the future. Lancet, 2011, 377: 1276–1287. https://doi.org/10.1016/S0140-6736(10)62349-5

Crossref Google Scholar
[73]

Foessl, I., Dimai, H. P., Obermayer-Pietsch, B. Long-term and sequential treatment for osteoporosis. Nature Reviews Endocrinology, 2023, 19: 520–533. https://doi.org/10.1038/s41574-023-00866-9

Crossref Google Scholar
[74]

Blake, J., Cosman, F. A., Lewiecki, E. M., et al. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause, 2021, 28: 973–997. https://doi.org/10.1097/GME.0000000000001831

Crossref Google Scholar
[75]

Khosla, S., Hofbauer, L. C. Osteoporosis treatment: recent developments and ongoing challenges. The Lancet. Diabetes & Endocrinology, 2017, 5: 898–907. https://doi.org/10.1016/S2213-8587(17)30188-2

Crossref Google Scholar
[76]
McClung, M. R., Grauer, A., Boonen, S., et al. Romosozumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine, 2014 , 370: 412–420. https://doi.org/10.1056/NEJMoa1305224
Crossref
[77]
Hartz, M. C., Johannessen, F. B., Harsløf, T., et al. The Effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. The Journal of Clinical Endocrinology and Metabolism, 2024 : dgae484. https://doi.org/10.1210/clinem/dgae484
Crossref
[78]
Zheng, J., Li, X., Zhang, F., et al. Targeting osteoblast-osteoclast cross-talk bone homeostasis repair microcarriers promotes intervertebral fusion in osteoporotic rats. Advanced Healthcare Materials, 2024 , 13: e2402117. https://doi.org/10.1002/adhm.202402117
Crossref
[79]
Rajput, S., Kulkarni, C., Sharma, S., et al. Osteogenic effect of an adiponectin-derived short peptide that rebalances bone remodeling: a potential disease-modifying approach for postmenopausal osteoporosis therapy. Archives of Pharmacal Research, 2024 , 47: 736–755. https://doi.org/10.1007/s12272-024-01509-x
Crossref
[80]
He, J., Zhao, D., Peng, B., et al. A novel mechanism of Vildagliptin in regulating bone metabolism and mitigating osteoporosis. International Immunopharmacology, 2024 , 130: 111671. https://doi.org/10.1016/j.intimp.2024.111671
Crossref
[81]

Cruz-Jentoft, A. J., Sayer, A. A. Sarcopenia. Lancet, 2019, 393: 2636–2646. https://doi.org/10.1016/S0140-6736(19)31138-9

Crossref Google Scholar
[82]
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019 , 48: 16–31. https://doi.org/10.1093/ageing/afy169
Crossref
[83]

Cho, M. R., Lee, S., Song, S. K. A Review of sarcopenia pathophysiology, diagnosis, treatment and future direction. Journal of Korean Medical Science, 2022, 37: e146. https://doi.org/10.3346/jkms.2022.37.e146

Crossref Google Scholar
[84]

Vitale, G., Cesari, M., Mari, D. Aging of the endocrine system and its potential impact on sarcopenia. European Journal of Internal Medicine, 2016, 35: 10–15. https://doi.org/10.1016/j.ejim.2016.07.017

Crossref Google Scholar
[85]

Dennison, E. M., Sayer, A. A., Cooper, C. Epidemiology of sarcopenia and insight into possible therapeutic targets. Nature Reviews Rheumatology, 2017, 13: 340–347. https://doi.org/10.1038/nrrheum.2017.60

Crossref Google Scholar
[86]
Todosenko, N., Yurova, K., Khaziakhmatova, O., et al. (Epi)genetic aspects of metabolic syndrome pathogenesis in relation to brain-derived neurotrophic factor expression: a review. Gene Expression, 2024 , 23: 127–138. https://doi.org/10.14218/GE.2023.00202
Crossref
[87]

Palmer, A. K., Jensen, M. D. Metabolic changes in aging humans: current evidence and therapeutic strategies. The Journal of Clinical Investigation, 2022, 132: e158451. https://doi.org/10.1172/JCI158451

Crossref Google Scholar
[88]

Batsis, J. A., Villareal, D. T. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature Reviews Endocrinology, 2018, 14: 513–537. https://doi.org/10.1038/s41574-018-0062-9

Crossref Google Scholar
[89]
Lisco, G., Disoteo, O. E., De Tullio, A., et al. Sarcopenia and diabetes: a detrimental liaison of advancing age. Nutrients, 2023 , 16: 63. https://doi.org/10.3390/nu16010063
Crossref
[90]

Kirk, B., Zanker, J., Duque, G. Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11: 609–618. https://doi.org/10.1002/jcsm.12567

Crossref Google Scholar
[91]
Bano, G., Trevisan, C., Carraro, S., et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas, 2017 , 96: 10–15. https://doi.org/10.1016/j.maturitas.2016.11.006
Crossref
[92]
Jimenez-Gutierrez, G. E., Martínez-Gómez, L. E., Martínez-Armenta, C., et al. Molecular mechanisms of inflammation in sarcopenia: diagnosis and therapeutic update. Cells, 2022 , 11: 2359. https://doi.org/10.3390/cells11152359
Crossref
[93]

Coletta, G., Phillips, S. M. An elusive consensus definition of sarcopenia impedes research and clinical treatment: a narrative review. Ageing Research Reviews, 2023, 86: 101883. https://doi.org/10.1016/j.arr.2023.101883

Crossref Google Scholar
[94]
Dent, E., Morley, J. E., Cruz-Jentoft, A. J., et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. The Journal of Nutrition, Health & Aging, 2018 , 22: 1148–1161. https://doi.org/10.1007/s12603-018-1139-9
Crossref
[95]

Sayer, A. A., Cruz-Jentoft, A. Sarcopenia definition, diagnosis and treatment: consensus is growing. Age and Ageing, 2022, 51: afac220. https://doi.org/10.1093/ageing/afac220

Crossref Google Scholar
[96]
Liu, C., Cheung, W. H., Li, J., et al. Understanding the gut microbiota and sarcopenia: a systematic review. Journal of Cachexia, Sarcopenia and Muscle, 2021 , 12: 1393–1407. https://doi.org/10.1002/jcsm.12784
Crossref
[97]
Kim, D. H., Kim, J., Park, J., et al. Blockade of forkhead box protein O1 signaling alleviates primary sclerosing cholangitis-induced sarcopenia in mice model. Life Sciences, 2024 , 356: 123042. https://doi.org/10.1016/j.lfs.2024.123042
Crossref
[98]
Huang, L., Jiao, Y., Xia, H., et al. Strontium zinc silicate simultaneously alleviates osteoporosis and sarcopenia in tail-suspended rats via Piezo1-mediated Ca2+ signaling. Journal of Orthopaedic Translation, 2024 , 48: 146–155. https://doi.org/10.1016/j.jot.2024.07.014
Crossref
[99]
Kim, H., Ranjit, R., Claflin, D. R., et al. Unacylated ghrelin protects against age-related loss of muscle mass and contractile dysfunction in skeletal muscle. Aging Cell, 2024 , 23: e14323. https://doi.org/10.1111/acel.14323
Crossref
[100]
Wu, Q., Xu, Z., Huang, W., et al. Effect of high plant protein/peptide nutrition supplementation on knee osteoarthritis in older adults with sarcopenia: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition, 2024 , 43: 2177–2185. https://doi.org/10.1016/j.clnu.2024.07.037
Crossref
[101]
Meng, T., Xiao, D., Muhammed, A., et al. Anti-Inflammatory action and mechanisms of resveratrol. Molecules, 2021 , 26: 229. https://doi.org/10.3390/molecules26010229
Crossref
[102]
Shahcheraghi, S. H., Salemi, F., Small, S., et al. Resveratrol regulates inflammation and improves oxidative stress via Nrf2 signaling pathway: therapeutic and biotechnological prospects. Phytotherapy Research, 2023 , 37: 1590–1605. https://doi.org/10.1002/ptr.7754
Crossref
[103]
Yu, H., Lin, L., Zhang, Z., et al. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduction and Targeted Therapy, 2020 , 5: 209. https://doi.org/10.1038/s41392-020-00312-6
Crossref
[104]
Sarubbo, F., Esteban, S., Miralles, A., et al. Effects of resveratrol and other polyphenols on Sirt1: relevance to brain function during aging. Current Neuropharmacology, 2018 , 16: 126–136. https://doi.org/10.2174/1570159X15666170703113212
Crossref
[105]

Chang, H. C., Guarente, L. SIRT1 and other sirtuins in metabolism. Trends in Endocrinology & Metabolism, 2014, 25: 138–145. https://doi.org/10.1016/j.tem.2013.12.001

Crossref Google Scholar
[106]
Yang, Y., Liu, Y., Wang, Y., et al. Regulation of SIRT1 and its roles in inflammation. Frontiers in Immunology, 2022 , 13: 831168. https://doi.org/10.3389/fimmu.2022.831168
Crossref
[107]

Kim, H. J., Braun, H. J., Dragoo, J. L. The effect of resveratrol on normal and osteoarthritic chondrocyte metabolism. Bone & Joint Research, 2014, 3: 51–59. https://doi.org/10.1302/2046-3758.33.2000226

Crossref Google Scholar
[108]

Singh, V., Ubaid, S. Role of silent information regulator 1 (SIRT1) in regulating oxidative stress and inflammation. Inflammation, 2020, 43: 1589–1598. https://doi.org/10.1007/s10753-020-01242-9

Crossref Google Scholar
[109]
Diaz-Gerevini, G. T., Repossi, G., Dain, A., et al. Beneficial action of resveratrol: How and why? Nutrition, 2016 , 32: 174–178. https://doi.org/10.1016/j.nut.2015.08.017
Crossref
[110]
Hori, Y. S., Kuno, A., Hosoda, R., et al. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One, 2013 , 8: e73875. https://doi.org/10.1371/journal.pone.0073875
Crossref
[111]
Wang, B., Wu, L., Chen, J., et al. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduction and Targeted Therapy, 2021 , 6: 94. https://doi.org/10.1038/s41392-020-00443-w
Crossref
[112]

Yarla, N. S., Bishayee, A., Sethi, G., et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Seminars in Cancer Biology, 2016, 40/41: 48–81. https://doi.org/10.1016/j.semcancer.2016.02.001

Crossref Google Scholar
[113]
Cianciulli, A., Calvello, R., Cavallo, P., et al. Modulation of NF-κB activation by resveratrol in LPS treated human intestinal cells results in downregulation of PGE2 production and COX-2 expression. Toxicology in Vitro, 2012 , 26: 1122–1128. https://doi.org/10.1016/j.tiv.2012.06.015
Crossref
[114]
Xin, M., Wu, H., Du, Y., et al. Synthesis and biological evaluation of resveratrol amide derivatives as selective COX-2 inhibitors. Chemico-biological Interactions, 2023 , 380: 110522. https://doi.org/10.1016/j.cbi.2023.110522
Crossref
[115]
Guo, Y. J., Pan, W. W., Liu, S. B., et al. ERK/MAPK signalling pathway and tumorigenesis. Experimental and Therapeutic Medicine, 2020 , 19: 1997–2007. https://doi.org/10.3892/etm.2020.8454
Crossref
[116]

Fang, J. Y., Richardson, B. C. The MAPK signalling pathways and colorectal cancer. The Lancet. Oncology, 2005, 6: 322–327. https://doi.org/10.1016/S1470-2045(05)70168-6

Crossref Google Scholar
[117]
Behl, T., Rana, T., Alotaibi, G. H., et al. Polyphenols inhibiting MAPK signalling pathway mediated oxidative stress and inflammation in depression. Biomedicine & pharmacotherapy, 2022 , 146: 112545. https://doi.org/10.1016/j.biopha.2021.112545
Crossref
[118]

He, F., Antonucci, L., Karin, M. NRF2 as a regulator of cell metabolism and inflammation in cancer. Carcinogenesis, 2020, 41: 405–416. https://doi.org/10.1093/carcin/bgaa039

Crossref Google Scholar
[119]
Ahmed, S. M., Luo, L., Namani, A., et al. Nrf2 signaling pathway: pivotal roles in inflammation. Biochimica et Biophysica Acta, 2017 , 1863: 585–597. https://doi.org/10.1016/j.bbadis.2016.11.005
Crossref
[120]
Saha, S., Buttari, B., Panieri, E., et al. An overview of Nrf2 signaling pathway and its role in inflammation. Molecules, 2020 , 25: 5474. https://doi.org/10.3390/molecules25225474
Crossref
[121]

Harris, I. S., DeNicola, G. M. The complex interplay between antioxidants and ROS in cancer. Trends in Cell Biology, 2020, 30: 440–451. https://doi.org/10.1016/j.tcb.2020.03.002

Crossref Google Scholar
[122]

Medzhitov, R. Origin and physiological roles of inflammation. Nature, 2008, 454: 428–435. https://doi.org/10.1038/nature07201

Crossref Google Scholar
[123]

Medzhitov, R. The spectrum of inflammatory responses. Science, 2021, 374: 1070–1075. https://doi.org/10.1126/science.abi5200

Crossref Google Scholar
[124]

Toniolo, L., Concato, M., Giacomello, E. Resveratrol, a multitasking molecule that improves skeletal muscle health. Nutrients, 2023, 15: 3413. https://doi.org/10.3390/nu15153413

Crossref Google Scholar
[125]
Liang, C., Xing, H., Wang, C., et al. Resveratrol protection against IL-1β-induced chondrocyte damage via the SIRT1/FOXO1 signaling pathway. Journal of Orthopaedic Surgery and Research, 2022 , 17: 406. https://doi.org/10.1186/s13018-022-03306-y
Crossref
[126]
Yi, H., Zhang, W., Cui, Z. M., et al. Resveratrol alleviates the interleukin-1β-induced chondrocytes injury through the NF-κB signaling pathway. Journal of Orthopaedic Surgery and Research, 2020 , 15: 424. https://doi.org/10.1186/s13018-020-01944-8
Crossref
[127]

Wang, X., Chen, L., Peng, W. Protective effects of resveratrol on osteoporosis via activation of the SIRT1-NF-κB signaling pathway in rats. Experimental and Therapeutic Medicine, 2017, 14: 5032–5038. https://doi.org/10.3892/etm.2017.5147

Crossref Google Scholar
[128]
Zhang, Y., Liu, M. W., He, Y., et al. Protective effect of resveratrol on estrogen deficiency-induced osteoporosis though attenuating NADPH oxidase 4/nuclear factor kappa B pathway by increasing miR-92b-3p expression. International Journal of Immunopathology and Pharmacology, 2020 , 34: 2058738420941762. https://doi.org/10.1177/2058738420941762
Crossref
[129]
Lin, T. C., Lin, J. N., Yang, I. H., et al. The combination of resveratrol and Bletilla striata polysaccharide decreases inflammatory markers of early osteoarthritis knee and the preliminary results on LPS-induced OA rats. Bioengineering & Translational Medicine, 2023 , 8: e10431. https://doi.org/10.1002/btm2.10431
Crossref
[130]
Liu, F. C., Hung, L. F., Wu, W. L., et al. Chondroprotective effects and mechanisms of resveratrol in advanced glycation end products-stimulated chondrocytes. Arthritis research & Therapy, 2010 , 12: R167. https://doi.org/10.1186/ar3127
Crossref
[131]
Mehta, S., Young, C. C., Warren, M. R., et al. Resveratrol and curcumin attenuate ex vivo sugar-induced cartilage glycation, stiffening, senescence, and degeneration. Cartilage, 2021 , 13: 1214S-1228S. https://doi.org/10.1177/1947603520988768
Crossref
[132]
Shu, M., Cheng, W., Jia, X., et al. AGEs promote atherosclerosis by increasing LDL transcytosis across endothelial cells via RAGE/NF-κB/Caveolin-1 pathway. Molecular Medicine, 2023 , 29: 113. https://doi.org/10.1186/s10020-023-00715-5
Crossref
[133]
Mohammad, R. M., Muqbil, I., Lowe, L., et al. Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 2015 , 35: S78–103. https://doi.org/10.1016/j.semcancer.2015.03.001
Crossref
[134]

Tower, J. Programmed cell death in aging. Ageing Research Reviews, 2015, 23: 90–100. https://doi.org/10.1016/j.arr.2015.04.002

Crossref Google Scholar
[135]
Nguyen, T. T., Wei, S., Nguyen, T. H., et al. Mitochondria-associated programmed cell death as a therapeutic target for age-related disease. Experimental & Molecular Medicine, 2023 , 55: 1595–1619. https://doi.org/10.1038/s12276-023-01046-5
Crossref
[136]

Zorov, D. B., Juhaszova, M., Sollott, S. J. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiological Reviews, 2014, 94: 909–950. https://doi.org/10.1152/physrev.00026.2013

Crossref Google Scholar
[137]
Riegger, J., Schoppa, A., Ruths, L., et al. Oxidative stress as a key modulator of cell fate decision in osteoarthritis and osteoporosis: a narrative review. Cellular & Molecular Biology Letters, 2023 , 28: 76. https://doi.org/10.1186/s11658-023-00489-y
Crossref
[138]
Li, C. W., Yu, K., Shyh-Chang, N., et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. Journal of Cachexia, Sarcopenia and Muscle, 2022 , 13: 781–794. https://doi.org/10.1002/jcsm.12901
Crossref
[139]
Xiang, Q., Zhao, Y., Lin, J., et al. The Nrf2 antioxidant defense system in intervertebral disc degeneration: molecular insights. Experimental & Molecular Medicine, 2022 , 54: 1067–1075. https://doi.org/10.1038/s12276-022-00829-6
Crossref
[140]
Barber, T. M., Kabisch, S., Randeva, H. S., et al. Implications of resveratrol in obesity and insulin resistance: a state-of-the-art review. Nutrients, 2022 , 14: 2870. https://doi.org/10.3390/nu14142870
Crossref
[141]

Bortoluzzi, A., Furini, F., Scirè, C. A. Osteoarthritis and its management-epidemiology, nutritional aspects and environmental factors. Autoimmunity Reviews, 2018, 17: 1097–1104. https://doi.org/10.1016/j.autrev.2018.06.002

Crossref Google Scholar
[142]

Lee, K. Association of osteosarcopenic obesity and its components: osteoporosis, sarcopenia and obesity with insulin resistance. Journal of Bone and Mineral Metabolism, 2020, 38: 695–701. https://doi.org/10.1007/s00774-020-01104-2

Crossref Google Scholar
[143]

Herzig, S., Shaw, R. J. AMPK: guardian of metabolism and mitochondrial homeostasis. Nature Reviews. Molecular Cell Biology, 2018, 19: 121–135. https://doi.org/10.1038/nrm.2017.95

Crossref Google Scholar
[144]
Wang, J., Gao, J. S., Chen, J. W., et al. Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatology International, 2012 , 32: 1541–1548. https://doi.org/10.1007/s00296-010-1720-y
Crossref
[145]
Jin, H., Liang, Q., Chen, T., et al. Resveratrol protects chondrocytes from apoptosis via altering the ultrastructural and biomechanical properties: an AFM study. PLoS One, 2014 , 9: e91611. https://doi.org/10.1371/journal.pone.0091611
Crossref
[146]
Yuce, P., Hosgor, H., Rencber, S. F., et al. Effects of intra-articular resveratrol injections on cartilage destruction and synovial inflammation in experimental temporomandibular joint osteoarthritis. Journal of Oral and Maxillofacial Surgery, 2021 , 79: 344. https://doi.org/10.1016/j.joms.2020.09.015
Crossref
[147]
Zhao, J., Zhou, G., Yang, J., et al. Effects of resveratrol in an animal model of osteoporosis: a meta-analysis of preclinical evidence. Frontiers in Nutrition, 2023 , 10: 1234756. https://doi.org/10.3389/fnut.2023.1234756
Crossref
[148]
Lin, F., Chen, J., Chen, M., et al. Protective effect and possible mechanisms of resveratrol in animal models of osteoporosis: a preclinical systematic review and meta-analysis. Phytotherapy Research, 2023 , 37: 5223–5242. https://doi.org/10.1002/ptr.7954
Crossref
[149]
Jiang, Y., Luo, W., Wang, B., et al. Resveratrol promotes osteogenesis via activating SIRT1/FoxO1 pathway in osteoporosis mice. Life Sciences, 2020 , 246: 117422. https://doi.org/10.1016/j.lfs.2020.117422
Crossref
[150]
Zhang, J., Li, R., Man, K., et al. Enhancing osteogenic potential of hDPSCs by resveratrol through reducing oxidative stress via the Sirt1/Nrf2 pathway. Pharmaceutical Biology, 2022 , 60: 501–508. https://doi.org/10.1080/13880209.2022.2037664
Crossref
[151]
Yang, X., Jiang, T., Wang, Y., et al. The role and mechanism of SIRT1 in resveratrol-regulated osteoblast autophagy in osteoporosis rats. Scientific Reports, 2019 , 9: 18424. https://doi.org/10.1038/s41598-019-44766-3
Crossref
[152]

Malaguarnera, L. Influence of resveratrol on the immune response. Nutrients, 2019, 11: 946. https://doi.org/10.3390/nu11050946

Crossref Google Scholar
[153]
Thapa, R., Moglad, E., Afzal, M., et al. The role of sirtuin 1 in ageing and neurodegenerative disease: a molecular perspective. Ageing Research Reviews, 2024 , 102: 102545. https://doi.org/10.1016/j.arr.2024.102545
Crossref
[154]
Huang, C. C., Lee, M. C., Ho, C. S., et al. Protective and recovery effects of resveratrol supplementation on exercise performance and muscle damage following acute plyometric exercise. Nutrients, 2021 , 13: 3217. https://doi.org/10.3390/nu13093217
Crossref
[155]

Wan, M. L. Y., Co, V. A., El-Nezami, H. Dietary polyphenol impact on gut health and microbiota. Critical Reviews in Food Science and Nutrition, 2021, 61: 690–711. https://doi.org/10.1080/10408398.2020.1744512

Crossref Google Scholar
[156]

Schwingshackl, L., Morze, J., Hoffmann, G. Mediterranean diet and health status: active ingredients and pharmacological mechanisms. British Journal of Pharmacology, 2020, 177: 1241–1257. https://doi.org/10.1111/bph.14778

Crossref Google Scholar
[157]
Lin, X., Zhao, J., Ge, S., et al. Dietary polyphenol intake and risk of hypertension: an 18-y nationwide cohort study in China. The American Journal of Clinical Nutrition, 2023 , 118: 264–272. https://doi.org/10.1016/j.ajcnut.2023.05.001
Crossref
[158]
Rosato, V., Temple, N. J., La Vecchia, C., et al. Mediterranean diet and cardiovascular disease: a systematic review and meta-analysis of observational studies. European Journal of Nutrition, 2019 , 58: 173–191. https://doi.org/10.1007/s00394-017-1582-0
Crossref
[159]
Becerra-Tomás, N., Blanco Mejía, S., Viguiliouk, E., et al. Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic review and meta-analysis of prospective cohort studies and randomized clinical trials. Critical Reviews in Food Science and Nutrition, 2020 , 60: 1207–1227. https://doi.org/10.1080/10408398.2019.1565281
Crossref
[160]
Huang, L., Tao, Y., Chen, H., et al. Mediterranean-Dietary approaches to stop hypertension intervention for neurodegenerative delay (MIND) diet and cognitive function and its decline: a prospective study and meta-analysis of cohort studies. The American Journal of Clinical Nutrition, 2023 , 118: 174–182. https://doi.org/10.1016/j.ajcnut.2023.04.025
Crossref
[161]
Harper, S. A., Bassler, J. R., Peramsetty, S., et al. Resveratrol and exercise combined to treat functional limitations in late life: a pilot randomized controlled trial. Experimental Gerontology, 2021 , 143: 111111. https://doi.org/10.1016/j.exger.2020.111111
Crossref
[162]
Ornstrup, M. J., Harsløf, T., Kjær, T. N., et al. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. The Journal of Clinical Endocrinology and Metabolism, 2014 , 99: 4720–4729. https://doi.org/10.1210/jc.2014-2799
Crossref
[163]

Marouf, B. H. Effect of resveratrol on serum levels of type II collagen and aggrecan in patients with knee osteoarthritis: a pilot clinical study. BioMed Research International, 2021, 2021: 3668568. https://doi.org/10.1155/2021/3668568

Crossref Google Scholar
[164]
Hussain, S. A., Marouf, B. H., Ali, Z. S., et al. Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study. Clinical Interventions in Aging, 2018 , 13: 1621–1630. https://doi.org/10.2147/CIA.S172758
Crossref
[165]
Corbi, G., Nobile, V., Conti, V., et al. Equol and resveratrol improve bone turnover biomarkers in postmenopausal women: a clinical trial. International Journal of Molecular Sciences, 2023 , 24: 12063. https://doi.org/10.3390/ijms241512063
Crossref
[166]
Nguyen, C., Coudeyre, E., Boutron, I., et al. Oral resveratrol in adults with knee osteoarthritis: a randomized placebo-controlled trial (ARTHROL). PLoS Medicine, 2024 , 21: e1004440. https://doi.org/10.1371/journal.pmed.1004440
Crossref
[167]

Vesely, O., Baldovska, S., Kolesarova, A. Enhancing bioavailability of nutraceutically used resveratrol and other stilbenoids. Nutrients, 2021, 13: 3095. https://doi.org/10.3390/nu13093095

Crossref Google Scholar
[168]
Cheng, C. K., Luo, J. Y., Lau, C. W., et al. Pharmacological basis and new insights of resveratrol action in the cardiovascular system. British Journal of Pharmacology, 2020 , 177: 1258–1277. https://doi.org/10.1111/bph.14801
Crossref
[169]
Rubinstein, A. J., Garcia Liñares, G., Boeris, V., et al. An innovative bio-vehicle for resveratrol and tocopherol based on quinoa 11S globulin-nanocomplex design and characterization. Pharmaceutics, 2024 , 16: 1118. https://doi.org/10.3390/pharmaceutics16091118
Crossref
[170]
Zhu, H., Fan, J., Yang, C., et al. DNA nanocarriers for delivery of sgRNA/Cas9 ribonucleoprotein. Nano Biomedicine and Engineering, 2024 , 16: 331–344. https://doi.org/10.26599/NBE.2024.9290096
Crossref
[171]

Du Preez, H. N., Halma, M. Graphene-based nanomaterials: uses, environmental fate, and human health hazards. Nano Biomedicine and Engineering, 2024, 16: 219–231. https://doi.org/10.26599/NBE.2024.9290059

Crossref Google Scholar
[172]
Borsani, E., Bonazza, V., Buffoli, B., et al. Beneficial effects of concentrated growth factors and resveratrol on human osteoblasts in vitro treated with bisphosphonates. BioMed Research International, 2018 , 2018: 4597321. https://doi.org/10.1155/2018/4597321
Crossref
[173]

Wei, Y., Jia, J., Jin, X., et al. Resveratrol ameliorates inflammatory damage and protects against osteoarthritis in a rat model of osteoarthritis. Molecular medicine reports, 2018, 17: 1493–1498. https://doi.org/10.3892/mmr.2017.8036

Crossref Google Scholar
[174]

Feng, Y. L., Jiang, X. T., Ma, F. F., et al. Resveratrol prevents osteoporosis by upregulating FoxO1 transcriptional activity. International journal of molecular medicine, 2018, 41: 202–212. https://doi.org/10.3892/ijmm.2017.3208

Crossref Google Scholar
[175]

Lee, Y. J., Ahn, J. C., & Oh, C. H. Oxyresveratrol attenuates bone resorption by inhibiting the mitogen-activated protein kinase pathway in ovariectomized rats. Nutrition & metabolism, 2024, 21: 7. https://doi.org/10.1186/s12986-024-00781-4

Crossref Google Scholar
[176]

Xuan, Y., Wang, J., Zhang, X., et al. Resveratrol Attenuates High Glucose-Induced Osteoblast Dysfunction via AKT/GSK3β/FYN-Mediated NRF2 Activation. Frontiers in pharmacology, 2022, 13: 862618. https://doi.org/10.3389/fphar.2022.862618

Crossref Google Scholar
[177]

Shabani, M., Sadeghi, A., Hosseini, H., et al. Resveratrol alleviates obesity-induced skeletal muscle inflammation via decreasing M1 macrophage polarization and increasing the regulatory T cell population. Scientific reports, 2020, 10: 3791. https://doi.org/10.1038/s41598-020-60185-1

Crossref Google Scholar
[178]

Shabani, M., Hosseini, H., Tajik, M. H., et al. Resveratrol relieves HFD-induced insulin resistance in skeletal muscle tissue through antioxidant capacity enhancement and the Nrf2-Keap1 signaling pathway. Molecular biology reports, 2024, 51: 516. https://doi.org/10.1007/s11033-024-09434-4

Crossref Google Scholar
[179]

Hosoda, R., Nakashima, R., Yano, M., et al. Resveratrol, a SIRT1 activator, attenuates aging-associated alterations in skeletal muscle and heart in mice. Journal of pharmacological sciences, 2023, 152: 112–122. https://doi.org/10.1016/j.jphs.2023.04.001

Crossref Google Scholar
[180]

Negro, M., Perna, S., Spadaccini, D., et al. Effects of 12 Weeks of Essential Amino Acids (EAA)-Based Multi-Ingredient Nutritional Supplementation on Muscle Mass, Muscle Strength, Muscle Power and Fatigue in Healthy Elderly Subjects: A Randomized Controlled Double-Blind Study. The journal of nutrition, health & aging, 2019, 23: 414–424. https://doi.org/10.1007/s12603-019-1163-4

Crossref Google Scholar
Food & Medicine Homology
DOI: 10.26599/FMH.2026.9420093
Cite this article:
Zhang X, Zhou H-F, Chen J-Y, et al. Resveratrol in degenerative musculoskeletal diseases: a homology of medicine and food perspective. Food & Medicine Homology, 2025, https://doi.org/10.26599/FMH.2026.9420093
Metrics & Citations  
Article History
Copyright
Rights and Permissions
Return